Results 1 to 10 of about 1,040,826 (380)

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation. [PDF]

Clin Cancer Res, 2023
Purpose: Cholangiocarcinoma (CCA) is usually diagnosed at advanced stages, with limited therapeutic options. Preclinical models focused on unresectable metastatic CCA are necessary to develop rational treatments. Pathogenic mutations in IDH1/2, ARID1A/B,
Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernadó-Morales C, Haro N, Giles FJ, Pozo ÓJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV.   +30 more
europepmc   +8 more sources

Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation. [PDF]

Trends Pharmacol Sci, 2023
Timely intervention of preventative and therapeutic measures abated a 2022 mpox global outbreak. However, the high transmissibility and unique pathological characteristics of mpox demand further investigation. Here, we discuss the potentials of human skin-on-a-chip as a valuable model for mpox disease evaluation, to achieve in-depth physiological ...
Zhu J, Abaci HE.
europepmc   +4 more sources

Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation. [PDF]

Sci Rep, 2017
Medulloblastomas comprise a heterogeneous group of tumours and can be subdivided into four molecular subgroups (WNT, SHH, Group 3 and Group 4) with distinct prognosis, biological behaviour and implications for targeted therapies.
Sandén E, Dyberg C, Krona C, Gallo-Oller G, Olsen TK, Enríquez Pérez J, Wickström M, Estekizadeh A, Kool M, Visse E, Ekström TJ, Siesjö P, Johnsen JI, Darabi A.   +13 more
europepmc   +2 more sources

Advancing preclinical drug evaluation through automated 3D imaging for high-throughput screening with kidney organoids. [PDF]

Biofabrication
High-throughput drug screening is crucial for advancing healthcare through drug discovery. However, a significant limitation arises from available in vitro models using conventional 2D cell culture, which lack the proper phenotypes and architectures ...
Oishi H, Tabibzadeh N, Morizane R.
europepmc   +2 more sources

Ex vivomicro-computed tomography analysis of bleomycin-induced lung fibrosis for preclinical drug evaluation [PDF]

European Respiratory Journal, 2013
Research into the pathogenesis underlying the development of idiopathic pulmonary fibrosis is hampered by a repertoire of animal models that fail to recapitulate all the features of the human disease.
Chris J. Scotton, Brian Hayes, Robert Alexander, Arnab Datta, Ellen Forty, Paul F. Mercer, Andy Blanchard, Rachel C. Chambers   +7 more
openalex   +2 more sources

Advances in preclinical evaluation of experimental antibody-drug conjugates

Cancer Drug Resistance, 2021
The ability to chemically modify monoclonal antibodies with the attachment of specific functional groups has opened up an enormous range of possibilities for the targeted treatment and diagnosis of cancer in the clinic. As the number of such antibody-based drug candidates has increased, so too has the need for more stringent and robust preclinical ...
Scott K. Lyons, Dennis Plenker, Lloyd C. Trotman   +2 more
openalex   +5 more sources

An Evaluation of the Efficacy of Preclinical Models of Lung Cancer Drugs [PDF]

, 2020
AbstractBackgroundPreclinical cell models are the mainstay in the early stages of drug development. We sought to explore the preclinical data that differentiated successful from failed therapeutic agents in lung cancer.Methods134 failed lung cancer drugs and 27 successful lung cancer drugs were identified. Preclinical data were evaluated.
Elizabeth Pan, David Bogumil, Victoria K. Cortessis, Sherrie Yu, Jorge J. Nieva   +4 more
openalex   +3 more sources

Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation

Pharmaceutics, 2022
Drug-induced cardiotoxicity not only leads to the attrition of drugs during development, but also contributes to the high morbidity and mortality rates of cardiovascular diseases. Comprehensive testing for proarrhythmic risks of drugs has been applied in
Xiaoli Tang, Zengwu Wang, Shengshou Hu, Bingying Zhou   +3 more
doaj   +2 more sources

Computational Approaches in Preclinical Studies on Drug Discovery and Development

Frontiers in Chemistry, 2020
Because undesirable pharmacokinetics and toxicity are significant reasons for the failure of drug development in the costly late stage, it has been widely recognized that drug ADMET properties should be considered as early as possible to reduce failure ...
Fengxu Wu, Fengxu Wu, Yuquan Zhou, Yuquan Zhou, Langhui Li, Langhui Li, Xianhuan Shen, Xianhuan Shen, Ganying Chen, Ganying Chen, Xiaoqing Wang, Xiaoqing Wang, Xianyang Liang, Xianyang Liang, Mengyuan Tan, Mengyuan Tan, Zunnan Huang, Zunnan Huang, Zunnan Huang   +18 more
doaj   +2 more sources

Application of genomics in preclinical drug safety evaluation. [PDF]

Basic & Clinical Pharmacology & Toxicology, 2006
Abstract: Understanding the response of biological systems to xenobiotics is fundamental to the evaluation of drug safety. Toxicologists have traditionally gathered pathological, morphological, chemical and biochemical information from in vivo studies of preclinical species in order to assess drug safety and to determine how new drugs can be safely ...
P. Lord, A. Nie, M. McMillian
semanticscholar   +4 more sources